Sanofi Spain has launched new mobile apps to help healthcare professionals in the country manage their patients with venous thromboembolism (VTE).

The free apps will run on iPhone, iPad and Android devices and will support prescribers who choose its anticoagulant Clexane (enoxaparin).

The drug is the leading low molecular weight heparin (LMWH), but is being challenged by new types of anticoagulants such as Bayer's Xarelto (rivaroxaban) and Boehringer Ingelheim's Pradaxa (dabigatran).

The first of Sanofi's new apps, CLX Dosis, is a dose calculator for LMWHs, based on the patient's weight, for the treatment of VTE, pulmonary embolism and deep vein thromobosis.

The second, CLX Cesarean, is another dose calculator for the prophylaxis treatment of VTE (venous thromboembolism) in women with risk factors for emergency caesarean-after labour.

Based on guidelines from the Royal College of Obstetricians and Gynaecologists, CLX Cesarean defines the dose of low molecular weight heparin prenatal and postnatal care to prevent the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Commenting on the launch of these two apps Sanofi said they should allow healthcare professionals to more quickly and more conveniently work out the correct dosing for LMWHs compared to consulting the guidelines in their paper-based form.

Meanwhile, the company has recently launched a third Clexane-focused app, CLX Caprini. This is based on Professor Joseph Caprini's model for evaluating and weighting the main risk factors for VTE in patients undergoing surgical procedures.

Digital inspiration for pharma on mobile, social media, strategy, best practice, regulations and more